Nippon India Pharma Fund - Dividend - Direct Plan

  • Previous Nav

  • Net Change on 23-09-2020

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview Dividend | Direct Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

The primary investment objective of the Scheme is to generate consistent returns by investing in equity / equity related or fixed income securities of Pharma and other associated companies

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
Nippon India Pharma Fund - Direct Plan Dividend Plan 1.64 18.10 57.27 20.02 8.95 17.21
S&P BSE Health Care 0.79 15.24 49.44 11.79 2.07 14.67
S&P BSE Health Care - TRI 0.82 15.56 50.49 12.54 2.73 14.27
S&P BSE SENSEX - TRI -1.97 6.89 -2.55 6.90 9.20 12.45

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
Nippon India Pharma Fund - Direct Plan Dividend Plan Jan 01, 2013 57.27 20.02 8.95 1.31 3,652.59
SBI HEALTHCARE OPPORTUNITIES FUND - DIRECT PLAN -DIVIDEND Jan 01, 2013 56.98 13.01 4.65 1.15 1,360.70
UTI Healthcare Fund -Direct Plan - Income Option Jan 01, 2013 60.51 16.19 6.37 1.85 563.44

Fund Holdings as on 31-August-2020

  • Divi's Laboratories Limited

  • Sun Pharmaceutical Industries Limited

  • Lupin Limited

  • Aurobindo Pharma Limited

  • Dr. Reddy's Laboratories Limited

  • Cipla Limited

  • Thyrocare Technologies Limited

  • Fortis Healthcare Limited

  • Cadila Healthcare Limited

  • Sanofi India Limited

  • Syngene International Limited

  • Abbott India Limited

  • Narayana Hrudayalaya Limited

  • Reverse Repo

  • Biocon Limited

  • Indoco Remedies Limited

  • Laurus Labs Limited

  • Alkem Laboratories Limited

  • Triparty Repo

  • Pfizer Limited

  • Healthcare Global Enterprises Limited

  • GlaxoSmithKline Pharmaceuticals Limited

  • Cash Margin - Derivatives

  • Net Current Assets

View More
  • Pharmaceuticals & Drugs

  • Hospital & Healthcare Services

  • Miscellaneous

View More

Fund Manager

Most Recent Dividend

  • 02/03/2020

  • 05/03/2019

  • 05/03/2018

  • 06/03/2017

  • 08/03/2016

  • 02/02/2015

  • 17/02/2014

  • Cash

  • Equity

View More

About Nippon India Pharma Fund

Scheme Analysis

Nippon India Pharma Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to Nippon India Mutual Fund. It was launched on 01-Jan-2013 and currently has an AUM of ₹3,652.59 crore. Nippon India Pharma Fund is benchmarked against S&P BSE Health Care as primary index and S&P BSE Health Care - TRI as primary index and S&P BSE SENSEX - TRI as secondary index.

The NAV of Nippon India Pharma Fund ended down ₹-1.06(-1.17%)yesterday to ₹89.6385.

Among its top 3 holdings the fund has exposure to Divi's Laboratories Limited, and

The Nippon India Pharma Fund is managed by Sailesh Raj Bhan and Kinjal Desai.

Fund House Contact

4th Floor, Tower A, Peninsula Business Park, Ganapatrao Kadam Marg, Lower Parel (W) Mumbai - 400 013

022-68087000
022-68087097